MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

MDT

88.42

-0.26%↓

VEEV

282.22

-0.26%↓

A

120.83

+0.49%↑

WBA

11.48

-0.09%↓

HQY

101.21

-1.67%↓

Search

Relay Therapeutics Inc

Fermé

SecteurSoins de santé

3.59 1.99

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.48

Max

3.74

Chiffres clés

By Trading Economics

Revenu

-1.1M

-77M

Ventes

7.7M

7.7M

BPA

-0.455

Marge bénéficiaire

-1,003.581

Employés

259

EBITDA

-1.2M

-85M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+257.8% upside

Dividendes

By Dow Jones

Prochains Résultats

5 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

39M

593M

Ouverture précédente

1.6

Clôture précédente

3.59

Sentiment de l'Actualité

By Acuity

50%

50%

163 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Relay Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 juil. 2025, 17:03 UTC

Principaux Mouvements du Marché

Furniture Companies Rise on U.S. Trade Deal With Vietnam

2 juil. 2025, 15:18 UTC

Principaux Mouvements du Marché

Mogo Shares Rally After Embrace of Bitcoin Into Holdings, Operations

2 juil. 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

2 juil. 2025, 23:45 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2 juil. 2025, 23:40 UTC

Market Talk

Gold Edges Lower Amid Hopes for More Trade Deals -- Market Talk

2 juil. 2025, 21:01 UTC

Acquisitions, Fusions, Rachats

AT&T Completes Sale of Entire Remaining 70% Stake in DIRECTV to TPG >T

2 juil. 2025, 21:01 UTC

Acquisitions, Fusions, Rachats

AT&T and TPG Close DIRECTV Transaction

2 juil. 2025, 20:26 UTC

Résultats

Rivian Stock Drops on Sales Decline. The Stakes Are High for the Rest of 2025. -- Barrons.com

2 juil. 2025, 20:22 UTC

Market Talk

Gold Rises Following Weak ADP Payroll Reading -- Market Talk

2 juil. 2025, 20:13 UTC

Market Talk

Oil Price Expectations Stable in Dallas Fed Survey -- Market Talk

2 juil. 2025, 19:09 UTC

Market Talk

Oil Futures Bounce in Defiance of Downbeat Data -- Market Talk

2 juil. 2025, 19:08 UTC

Market Talk

Dollar Trims Gains as Investors Brace for Cooling Jobs Market -- Market Talk

2 juil. 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Ticks Up Ahead of Storage Data -- Market Talk

2 juil. 2025, 18:08 UTC

Market Talk

Fossil Fuels Rule Energy Roost As U.S. Marks Independence -- Market Talk

2 juil. 2025, 17:06 UTC

Acquisitions, Fusions, Rachats

BCE: Maple Leafs, Raptors Rights Access Through Long-Term Agreement With Rogers, Subject to League Approvals

2 juil. 2025, 17:05 UTC

Acquisitions, Fusions, Rachats

BCE: Access to Content Rights for Toronto Maple Leafs, Toronto Raptors on TSN Secured Through 2043/2044 Season

2 juil. 2025, 17:04 UTC

Acquisitions, Fusions, Rachats

BCE: Proceeds of MLSE Stake Sale to Support Financing of Acquisition of Ziply Fiber

2 juil. 2025, 17:04 UTC

Acquisitions, Fusions, Rachats

BCE Inc. Concludes Sale of Minority Stake in Maple Leaf Sports & Entertainment

2 juil. 2025, 17:02 UTC

Acquisitions, Fusions, Rachats

Rogers Communications: Now Largest Owner With 75% Interest in Maple Leaf Sports & Entertainment

2 juil. 2025, 17:02 UTC

Acquisitions, Fusions, Rachats

Rogers Communications Closes Deal to Buy BCE's 37.5% Stake in Maple Leaf Sports & Entertainment for C$4.7B

2 juil. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

2 juil. 2025, 16:20 UTC

Market Talk

Cushing Crude Stock Slide Keeps Bid in WTI -- Market Talk

2 juil. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

2 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

2 juil. 2025, 16:11 UTC

Market Talk

Copper Prices Hold Higher on Supply Disruption, Tariff Uncertainty -- Market Talk

2 juil. 2025, 16:09 UTC

Market Talk

Gold Futures Rise, Recouping Some Losses -- Market Talk

2 juil. 2025, 15:59 UTC

Résultats

These Stocks Are Moving the Most Today: Tesla, Centene, Apple, Adobe, Rigetti Computing, Greenbrier, and More -- Barrons.com

2 juil. 2025, 15:17 UTC

Market Talk

Oil Market to Keep Close Watch on U.S. Payrolls -- Market Talk

2 juil. 2025, 15:08 UTC

Market Talk

Luxury Sector Should Report a Slowdown -- Market Talk

2 juil. 2025, 15:00 UTC

Acquisitions, Fusions, Rachats

Glencore: Merger of Viterra With Bunge Global Closed

Comparaison

Variation de prix

Relay Therapeutics Inc prévision

Objectif de Prix

By TipRanks

257.8% hausse

Prévisions sur 12 Mois

Moyen 12.38 USD  257.8%

Haut 17 USD

Bas 4 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

10 ratings

8

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

2.88 / 3.285Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Sentiment

By Acuity

163 / 380Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Moyen

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.